Abstract
Introduction: Immunotherapy is a wide-spreading therapeutic resource in oncology. The therapy is guided to improve the patient’s immune response to cancer cells, on the basis of the concept of immune surveillance by activating both cell-mediated and humoral immunity to fight cancer. Immunomodulatory monoclonal antibody therapy utilizes preformed monoclonal antibodies directed against molecular targets to regulate T-cell activation. There are three mechanisms involved in this kind of therapy: antibodies directed against the programmed death protein 1 (PD-1)/programmed death receptor ligand 1 (PD-L1), such as nivolumab and CTLA-4 inhibitors that prevent inhibition of the activated T-cells.
Material and Method: Different reveiw articles were reviewed to understand the differences in response assessment of immunotherapy as compared to conventional chemotherapy or radiotherapy when using F-18 FDG PET/CT.
Results: When using FDG PET/CT for response assessment, following important items should be considered: (1) Pseudoprogression: meaning that we can see transient enlargement of tumors or the appearance of new tumors followed by tumor shrinkage or long-term stability of tumor size. (2) Hyperprogression which is characterized by rapid increase in tumor burden (more than 50% increase compared to basal) and also time to treatment failure less than 2 months and more than 2 times increase in tumor growth rate, with deteriorating clinical condition. (3) Response to treatment is generally slower than with conventional cytotoxic chemotherapy. (4) Adverse effects (irAE) that are more easily diagnosed through FDG PET CT, than through conventional CT, and the importance of being able to recognize and report them sometimes life-threatening like pneumonitis or colitis. Also nuclear medicine physician should report inflammatory changes like drug induced sarcoid-like lymph nodes and differentiate from progression disease or splenic/liver SUV, moreover keeping in mind that there is evidence of good association between the presence of irAE and good answer to treatment. (5) Evolution of irAE comparing the actual PET with previous reporting the change in 18FDG uptake.
Conclusion: Reporting of F-18 FDG PET/CT after immunotherapy, should consider these different items: Pseudoprogression, hyperprogression, irAE, evolution of irAE, and other inflammatory signs related to immunotherapy to improve our methodology efficiency.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
2.1 Introduction
Immunotherapy is used to improve a patient’s immune response to cancer cells, on the basis of the concept of immune surveillance, by activating both cell-mediated and humoral immunity to fight cancer. Immunomodulatory monoclonal antibody therapy utilizes preformed monoclonal antibodies directed against molecular targets to regulate T-cell activation. There are three main mechanisms involved in this kind of therapy: antibodies directed against the programmed death protein 1; (PD-1)/programmed death receptor ligand 1 (PD-L1). The mechanism is to block the PD1 receptor in the lymphocyte, while anti PDL1 is localized in the oncologic cell. The most common anti-PD1 and PDL1 drugs are: nivolumab, pembrolizumab, or atezolizumab.
The other involved mechanism is to block CTLA-4 in the T lymphocyte, and the main drug using this mechanism is imiliprumab (Fig. 2.1).
The number of these drugs are increasing exponentially during the last time and also the indications and combination with chemotherapy and radiotherapy. In below figures, we see the main drugs approved in the USA by FDA for immunotherapy up to December 2018.
2.2 Patterns of Response
According to the Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumor, there are four patterns of interest: (a) pseudoprogression; (b) hyperprogression; (c) dissociated response; (d) durable response.
2.2.1 Pseudoprogression
Interpretative criteria in CT By restoring an efficient antitumor T-cell response, immunotherapy can be followed by pseudoprogression which is defined as an objective response following initial disease progression. For CT (computed tomography) based on these observations, new specific response criteria have been developed, a consensus guideline-iRECIST was developed by the RECIST working group for the use of modified Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) in cancer immunotherapy trials, including immune-related response criteria (irRC); defining the concept of unconfirmed progressive disease (uPD) that may be confirmed by a new radiological evaluation up to 12 weeks later [1]. This concept can only be considered when there is a clear clinical benefit (CB) of the patient meaning that we can see transient enlargement of tumors or the presence of new lesions and after sometime the tumor will respond to therapy. This pseudoprogression is expected in 15% of the patients treated with Ipilimumab and in 10 % of the patients treated with pembrolizumab in NSCLC.
To evaluate response to treatment we have different articles published. Hodi et al. [2] conducted a study-wide analysis and found that 12% of patients (51 of 411 patients) with melanoma treated with pembrolizumab were classified as responders or as having stable disease by immune response criteria [3]. Basically, four different forms of treatment response have been reported.
-
1.
Reduction in tumor size after treatment initiation in comparison to baseline.
-
2.
Initial increase of tumor size and/or new lesions followed by a decrease that meets criteria for partial or complete response in comparison to baseline.
-
3.
Initial increase in tumor size and/or new lesions followed by a stable course.
-
4.
Almost stable tumor size without any significant changes.
This pattern of increasing size is confirmed by biopsy as inflammatory cell infiltrates or necrosis, with subsequent decreased tumor burden.
Interpretative criteria in PET CT An iconic publication in EJNMMI: “FDG PET/CT for assessing tumor response to immunotherapy: Report on the EANM symposium on immune modulation” [4] includes these response criteria including a new category of unconfirmed progression (iUPD) to be confirmed by a further follow-up scan. This can also include identification of new lesions. A good approach that I think is the best approach should consider these categories:
-
1.
Complete metabolic response (CMR) when there are no more detectable tumoral lesions in the 18 FDG PET/CT.
-
2.
Partial metabolic response (PMR) when there is a diminution of 15–25% of basal SUV after the first cycle and of 25% of the basal SUV after 2 cycles.
-
3.
Stable metabolic disease (SMD) decreases in less than 15% in SUVmax values or a decrease in 25% of the uptake after at least 2 cycles.
-
4.
Progressive metabolic disease (PMD) is defined as an increase in SUVmax of ≥25% from baseline imaging or the appearance of new metastatic lesions.
A good correlation between metastatic and new hypermetabolic lesions could be the application of the Heidelberg criteria, they describe a sensitivity (correctly predicting CB) of 84% and a specificity (correctly predicting No-CB) of 100%; this group uses functional size (the size of the lesion (in centimeters) as measured on the fused PET/CT images). This cut-off was lower for lesions with larger functional diameters:
-
(a)
Four new lesions of less than 1 cm
-
(b)
three new lesions larger than 1.0 cm
-
(c)
two new lesions larger than 1.5 cm
Although this approach is really practical, this work was done only for ipilimumab in melanoma, necessitating to validation for other drugs [5].
2.2.2 Hyperprogression
It is defined as an acceleration on tumor growth, there should be a duplication on tumor size in less than 2 months with clinical detrimental of the patients. The incidence is approximately in 15 % of the patients (5 % in patients with less than 65 years old and 20% in older patients). It is more common in patients over 65 treated with anti-PD1/PDL1 and in NSCLC, when this situation is suspected, the treatment should be immediately changed [5, 6].
Hyperprogression was observed in 29% of patients with head and neck cancer treated with antiPD-L1/PD-1 agents and correlated with a shorter PFS. It occurred in 39% of patients with at least a locoregional recurrence and 9% of patients with exclusively distant metastases [6].
Hyperprogressive disease in NSLC was significantly associated with more than 2 metastatic sites before PD-1/PD-L1 inhibitors compared with non-HPD (62.5% vs 42.6%) [7].
Some patients with MDM2 family amplification or EGFR aberrations had poor clinical outcome and significantly increased rate of tumor growth after single-agent checkpoint (PD-1/PD-L1) inhibitors [1].
The biological rationale may be related to that several primary and adaptive mechanisms of resistance to immunotherapy have been described. Response to immunotherapy seems to be conditioned by the infiltration of tumors by activated T-cells, other mechanism could be the absence of tumor recognition by T-cells, due to the lack of immunogenic tumor antigens, much more investigation should be done in this area.
Even with increasing published data on hyperprogression, its definition is not consensual. Some authors used only radiological criteria, based on the variation of three-dimensional or unidimensional measurements of tumor burden over time to evaluate the rate of tumor growth before and after immunotherapy initiation. However, there is no definite evidence of hyperprogression regarding metabolic imaging, most of the reviewed bibliography is supported on CT findings. In this point PD (progressive disease) is the most practical approach and doubling size in CT, for suspecting hyperprogression on 18F PET CT.
Dissociated Response
It is defined by a decrease or stabilization in some tumor sites with a concomitant increase in other sites.
Frequency: up to 10%.
It has better prognosis than homogeneous progression and these patients can benefit from adding other treatments like radiotherapy, surgery, or interventional radiology treatment.
It reflects the heterogeneity of tumors as well as their environment.
2.2.3 Durable Response
Female 60 y patient with melanoma resected and increased subcutaneous increased uptake (local persistent disease with increased uptake stable during 3 years.
Immunorelated Adverse Effects (irAE)
With these new drugs, more often with anti-PD1, there are adverse events related to immune activation, these effects are radically different from adverse effects related to cytotoxic drugs. Their presentation can range from mild and manageable, to severe and life threatening if not recognized early and treated with appropriate measures such as corticosteroids [8].The sensibility of PET CT for their diagnosis is much better than with others imaging modalities (CT), and the rapid identification and quick therapy, with immunosuppressive treatments, such as corticoids or TNFα antibody, improves patients evolution and allows to go on with the treatment [9]. Different irAE are more frequently seen with different drugs, e.g., ipilimumab, the first antibody approved by FDA, is seemingly more common with colitis and hypophysitis, while pneumonitis and thyroiditis are more common with nivolumab and pembrolizumab [10]. According to clinical reports, irAEs may occur at any time and cover multiple organs during the therapy (Fig. 2.2).
2.3 Mechanism
The involved mechanisms are suspected to be either a result of the induction of autoimmunity or a proinflammatory state [11]. Other situations related to the primary tumor are also supposed to be involved, like the tumor microenvironment (TME), immune infiltrate, adaptive immune response and neoantigen formation, so there are different incidences reported in different tumors.
2.4 18FPET CT and irAE
The possibility of identifying inflammatory changes with F-18 FDG PET CT allows us to better diagnose this situation. There are different irAE, and the focus should be on the ones that can be life threatening: 34% of the patients according to Fujii et al. [12]. In “Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience [11] experienced any grade of irAE, and 80% of them required systemic corticoids, and the most important conclusion related to this article is that this undesirable effects are associated to active immunostatus suggestive of potential clinical benefit for the patients. The incidence of these effects also is different according to the immune mechanism involved, and the frequency is with Anti CDLA 4: 54%; anti-PD1: 26%; anti PDL1: 13%. It is important for the imager to recognize the unique adverse events associated with immunotherapy to guide appropriate treatment and avoid potential imaging pitfalls that could be mistaken for metastatic progression of disease. The patterns that should be considered are:
-
Pneumonitis is a very rare adverse effect. It is more frequent in the patients with the use of anti-PD-1 than anti-PD-L1 or anti-CTLA-4. But the compounding of PD-1 and CTLA-4 blockade was reported significantly higher frequency of the pulmonary toxicity than either single immune-checkpoint inhibitors, up to 5–10% at any grade and 2% at 3–4 grade. It involves death risk. There are four radiological CT patterns described for this complication [13]: (1) cryptogenic organizing pneumonia (COP) in 65% of patients. (2) Non-specific interstitial pneumonia in 15% of patients. (3) Hypersensitivity pneumonia in 10% and (4) Acute interstitial pneumonia (AIP)/acute respiratory distress syndrome (ARDS) in 10%. Regarding the severity of the disease, there are 4 grades:
-
Grade 1 pneumonitis may be assessed by radiographic evidence and another CT may be repeated within 3–4 weeks to focus on the disease progression. Immunotherapy should be discontinued until improvement back to grade 1 or less, and administering prednisone under guidelines is essential for patients with grade 2 of pneumonitis. If pneumonitis is progressing to grade 3 or 4, it is suggested that immunotherapy should be ceased with the appropriate prescription of antibiotics and prednisolone. The median time to onset of pulmonary toxicity after initiation of immunotherapy is 2.3 months and tends to occur earlier in lung cancer (2.1 months) than in melanoma (5.2 months). Even after improvement of pneumonitis, occur with and without PD-1 antibody re-administration [14].
-
-
Colitis (more frequently within 6–7 weeks): It is associated to death risk when not treated as soon as diagnosed. Diarrhea and colitis are the main symptoms of gastrointestinal toxicities. In patients receiving ICPis, the incidence of all-grade diarrhea is reported to be higher with anti-CTLA-4 therapy, up to 30%. High grade diarrhea is also reported when nivolumab pluses ipilimumab, with the incidence up to 9%. There are two different patterns associated with Ipilimumab: Diffuse Pancolitis, that should be treated with corticoids, and during the diagnosis we should make the differential diagnosis with colitis related to oral hypoglycemics drug: many nuclear medicine departments stop metformin 24 h before 18FDG PET CT to avoid this situation. And segmental colitis which is associated with diverticulosis, restricted to a segment of colon and the treatment should include antibiotics [15]. In the CT we can see mesenteric vessel engorgement, bowel wall thickening (> 4mm irrespective of distension), or increased mucosal enhancement contrastct enhanced CT scan [16].
Male 66 years old renal cancer with pulmonary secundarism. Treated at first with sunitinib no answer, he started therapy with Nivolumab 6 months ago. We can see segmental colitis confirmed with endoscopy. Images courtesy of Dr. Marcelo Claria, jefe de Diagnóstico por imagen Sanatorio Allende. Córdoba-Argentina.
-
Pancolitis after Pembrolizumab in a patient treated for melanoma. Images courtesy of Dr. Marcelo Claria, jefe de Diagnóstico por imagen Sanatorio Allende. Córdoba-Argentina
-
Hepatitis: Starting at 3–9 weeks. The occurrence of hepatitis is less than 6% of patients receiving anti-PD-1 antibodies, about 7% of patients with CTLA-4 therapy and nearly 30% when CTLA-4 and PD-1/PD-L1 blockades are combined [17].
-
Adrenitis
-
Pancreatitis (−1%) in this case the typical pattern is increased diffuse uptake with the CT showing mildly enlarged pancreas with no peripancreatic inflammatory changes and rounded pancreatic contours that can be described as having the “sausage” appearance of autoimmune pancreatitis.
-
Hypophysitis for Aide et al. [4], suggest the importance of starting the PET/CT by including the whole of skull in patients treated with immunotherapy. Also magnetic resonance imaging (MRI) of pituitary gland manifests specific imaging characteristics of enlarged pituitary glands and stalks.
-
Thyroiditis: Thyropathy mainly includes primary hypothyroidism and hyperthyroidism, among which hypothyroidism is more common. Hypothyroidism generally develops at the 4th week with ipilimumab therapy and the 10th week in patients receiving nivolumab (more frequently between 7 and 20 weeks). It is very important to check that intense uptake deemed to be an immune-related sign was not present on the baseline scan, for example, diffuse thyroid uptake due to Hashimoto disease. Moreover 18F-FDG PET/CT can predict the development of thyroiditis with subsequent hypothyroidism before laboratory testing after immunotherapy with nivolumab for lung cancer [28].
-
Arthritis: shows diffuse periarticular FDG uptake in different joints like shoulders, elbow, wrists, hands, and hips.
-
Gastritis
-
Myocarditis
There are also other undesirable effects like dermatitis (such as rash, pruritus, and vitiligo but also may appear more serious effects like bullous pemphigoid, scleroderma-like skin changes, and severe cutaneous adverse reactions), fatigue, etc. not able to be recognized by 18FDG PET/CT.
It is also very important to compare previous studies, and to pay special attention to this irAE evolution in terms of metabolic behavior.
Incidence of irAEs with immunotherapeutic agents indicates an active immune status, suggestive of potential clinical benefit to the patient [12].
2.4.1 Therapy-Related Inflammation and Inverse Relation Liver SUV/Spleen SUV [18]
18F-FDG PET can help in the differentiation between progression and therapy-related inflammation, to define inflammatory changes it is important to consider particular patterns of tracer uptake [19]. Metabolic information provided by PET/CT is very important. And some items should be considered in lymph nodes and spleen. There are some important facts to consider regards lymph nodes:
Reactive nodes in the drainage basin of the primary tumor may be seen.
Reaction sarcoidosis like (5–7%) increased FDG uptake in mediastinal/hiliar nodes and may be in spleen. Symmetrical bilateral pattern of uptake in thorax, in enlarged hiliar/mediastinal lymph nodes suggesting sarcoidosis: lambda sign with or without portocaval nodes.
Preservation of fatty hilum.
In patients with good evolution with the previous characteristics, FDG avidity can be a marker of immune activation rather than progressive disease [20]
2.5 Conclusion
There are four patterns when reporting 18FDG PET CT after immunotherapy that should be considered (a) pseudoprogression; (b) hyperprogression; (c) dissociated response; (d) durable response. Immune related adverse events should be considered and reported, as well as therapy-related inflammation like sarcoidosis like reaction are immunotherapy-related findings. It is necessary to write a practical guide for reporting these findings in order to harmonize our results.
References
Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–50.
Hodi F, Ribas A, Daud A, et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;32(15):3006.
Kim HK, Baek S-W, Jeong Y, Yang Y, Kwon J, Han HS, An J-Y, Woo CG, Lee O-J, Lee TG, Lee KH. Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: a case report. Mol Clin Oncol. 2019;11(2):132–4.
Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238–50.
Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria J-C, Ferté C. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:8.
Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28:7.
Ferrara R, Caramella C, Texier M, Audigier Valette C, Tessonnier L, Mezquita L, Lahmar J, Mazieres J, Zalcman G, Brossea S, Westee V, Le Moulec S, Leroy L, Duchemann B, Veillon R, Planchard D, Boucher M, Koscielny S. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent. JAMA Oncol. 2018;4:1543–52.
Fujii T, Colen RR, Bilen MA, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investig New Drugs. 2018;36:638–46. https://doi.org/10.1007/s10637-017-0534-0.
Cousin S, Italiano A. Molecular pathways: immune checkpoint. Clin Cancer Res. 2016;22:4550–6.
Liu Y-H, Zang X-Y, Wang J-C, Huang S-S, Jiang X, Zhang P. Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy. Biomed Pharmacother. 2019;120:109437. https://doi.org/10.1016/j.biopha.2019.109437.
Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–9.
Fujii T; Colen RR; Bilen MA; Hess KR; Hajjar J; Suarez-Almazor ME; Alshawa A; Hong DS; Tsimberidou A; Janku F; Gong J; Stephen B; Subbiah V; Piha-Paul SA; Fu S; Sharma P; Mendoza T; Patel A; Thirumurthi S; Sheshadri A; Meric-Bernstam. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 2018; 36(4): 636-646. DOI: https://doi.org/10.1007/s10637-017-0534-0
Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Patrick A, Armand PF, Stephen F. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course, vol. 22. Clin Cancer Res; 2015. p. 24.
Koyauchi T, Inui N, Karayama M, et al. Clinical outcomes of anti-programmed death-1 antibody–related pneumonitis in patients with non-small cell lung cancer. SN Compr Clin Med. 2020;2:570–8. https://doi.org/10.1007/s42399-020-00259-3.
Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, Ibrahim N. Ipilimumab-associated colitis: CT findings. Am J Roentgenol. 2013;200(5):468–74.
Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Stephen Hodi F, Nishino M. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92. https://doi.org/10.1158/2326-6066.CIR-15-0102.
Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist. 2018;23(9):991–7. https://doi.org/10.1634/theoncologist.2018-0174. Epub 2018 May 31.
Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376–83. https://doi.org/10.1007/s00259-017-3870-6.
Sachpekidis C, Anwar H, Winkler J, et al. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018;45:1289–96. https://doi.org/10.1007/s00259-018-3972-9.
Tsai KK, Pampaloni MH, Hope C, et al. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016;4:58. https://doi.org/10.1186/s40425-016-0162-9.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz L, Mandrekar S. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:143–52.
Han B, Ryu J, Moon D, Shin M, Kim Y, L. HK. Bone SPECT imaging of vertebral hemangioma correlation with MR imaging and symptoms. Clin Nucl Med. 1995;20(10):916–21.
Beer L, Hochmair M, Prosch H. Pitfalls in the radiological response assessment of immunotherapy. Memory. 2018;11(2):138–43.
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.
Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.
Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Oxford Acad J. 2017;28:1605–11.
Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376–83. https://doi.org/10.1007/s00259-017-3870-6.
Wong AN, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44(1):67–77. https://doi.org/10.1007/s00259-017-3691-7. Epub 2017 Apr 7.
Raad RA, Pavlick AC, Friedman K. Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma. Clin Nucl Med. 2015;40(3):258–9. https://doi.org/10.1097/RLU.0000000000000606.
Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH. 18F-FDG PET/CT can predict development of thyroiditis due to immunotherapy for lung cancer. J Nucl Med Technol. 2018;46(3):260–4.
Evangelista L. Molecular imaging and immunotherapy. Int J Biol Markers. 2020;35(1):37–41. https://doi.org/10.1177/1724600819899099.
Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans AWJM, Weber W, Wahl RL, Scott AM, Pandit-Taskar N, Aide N. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022;49(7):2323–41. https://doi.org/10.1007/s00259-022-05780-2. Epub 2022 Apr 4. PMID: 35376991; PMCID: PMC9165250.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2024 The Author(s)
About this chapter
Cite this chapter
Agolti, M., Solari, L. (2024). Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment. In: Prasad, V. (eds) Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer, Cham. https://doi.org/10.1007/978-3-031-33533-4_2
Download citation
DOI: https://doi.org/10.1007/978-3-031-33533-4_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-33532-7
Online ISBN: 978-3-031-33533-4
eBook Packages: MedicineMedicine (R0)